Loading...

URGN UROGEN PHARMA LTD Investments/Divestments 8-K Filing

RGN

RGN

UROGEN PHARMA LTD

(URGN)

2024 8-K

Show Summary

Show Summary

New Product Launches

Financial Statements

Financial Results

Asset Acquisition

Investor Presentation

Financial Results

Director Resignation

Financial Results

Annual Meeting Approval

Public Offering

Positive Data from Phase 3 ...

Financial Results Announcement

Financial Results Announcement

Presentation at Conference

Notice of ANDA Submission

Agreement and Phase 3 Study

Amendment to Manufacturing ...

Financial Results Announcement

Annual Meeting of Shareholders

Financial Results Announcement

Private Placement

Financial Results Announcement

External Links:

Urogen Pharma announced positive data from a Phase 3 trial of UGN-102 for bladder cancer, with potential FDA approval expected in Q1 2025 and a total addressable market opportunity of over $5.0 billion.

AI Assistant

UROGEN PHARMA LTD

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.